Form 8-K · Current Report · Filed 2025-02-27
Crinetics Pharmaceuticals Reports 2024 Financial Results and Business Update
Crinetics Pharmaceuticals, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. The company's New Drug Application (NDA) for paltusotine for acromegaly was accepted for review by the FDA, with a PDUFA target action date of September 25, 2025. The company also reported positive results from clinical trials for paltusotine in carcinoid syndrome and atumelnant in congenital adrenal hyperplasia. The company's cash position of $1.4 billion is expected to support operations into 2029.
- Filer
- Crinetics Pharmaceuticals Inc. CRNX · NASDAQ
- Filed
- Accession
- 0000950170-25-029040
- CIK
- 0001658247
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$32.55
Next session
+9.9%
Since filing
+156.6%
Latest close
$83.52
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from CRNX reporting the same item, with the next session's move:
Exhibits (1)
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Never miss another CRNX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.